Advertisement

Latest Conference Articles

Educated Patient® Breast Cancer Summit at MBCB Hormone Receptor-Positive and TNBC Panel: March 4, 2023

Educated Patient® Breast Cancer Summit at MBCB Hormone Receptor-Positive and TNBC Panel: March 4, 2023

March 24th 2023, 1:00pm

Educated Patient® Breast Cancer Summit at MBCC: March 4, 2023

Watch Dr. William J Gradishar, Dr. Kevin Kalinsky and Kelly Thomas answer questions about hormone receptor-positive and triple-negative breast cancer treatment options during the CURE Educated Patient® Breast Cancer Summit at MBCC.

Educated Patient® Breast Cancer Summit at MBCC Triple-Negative Breast Cancer Treatment Presentation: March 4, 2023

Educated Patient® Breast Cancer Summit at MBCC Triple-Negative Breast Cancer Treatment Presentation: March 4, 2023

March 23rd 2023, 1:00pm

Educated Patient® Breast Cancer Summit at MBCC: March 4, 2023

Watch Dr. Kevin Kalisnky, from Winship Cancer Institute of Emory University, discuss treatment for triple-negative disease during the CURE Educated Patient® Breast Cancer Summit at MBCC.

Educated Patient® Breast Cancer Summit at MBCC Management of Hormone Receptor-Positive Breast Cancer Presentation: March 4, 2023

Educated Patient® Breast Cancer Summit at MBCC Management of Hormone Receptor-Positive Breast Cancer Presentation: March 4, 2023

March 22nd 2023, 1:00pm

Educated Patient® Breast Cancer Summit at MBCC: March 4, 2023

Watch Dr. William J. Gradishar, from Northwestern University, discuss the management of hormone receptor-positive disease during the CURE Educated Patient® Breast Cancer Summit at MBCC.

Educated Patient® Breast Cancer Summit at MBCC Nursing Perspective on Clinical Trials Presentation: March 4, 2023

Educated Patient® Breast Cancer Summit at MBCC Nursing Perspective on Clinical Trials Presentation: March 4, 2023

March 21st 2023, 1:00pm

Educated Patient® Breast Cancer Summit at MBCC: March 4, 2023

Watch Isabel Octaviano, from Miami Cancer Institute, Baptist Health South Florida, discuss the nursing perspective to clinical trials during the CURE Educated Patient® Breast Cancer Summit at MBCC.

Educated Patient® Breast Cancer Summit at MBCC Demystifying Clinical Trials Presentation: March 4, 2023

Educated Patient® Breast Cancer Summit at MBCC Demystifying Clinical Trials Presentation: March 4, 2023

March 20th 2023, 1:00pm

Educated Patient® Breast Cancer Summit at MBCC: March 4, 2023

Watch Dr. Reshma Mahtani, from Miami Cancer Institute, Baptist Health South Florida, discuss clinical trial myths during the CURE Educated Patient® Breast Cancer Summit at MBCC.

An Expert Discusses Nubeqa Side Effects Patients With Side Effects Should Know About

An Expert Discusses Nubeqa Side Effects Patients With Side Effects Should Know About

March 2nd 2023, 10:00pm

ASCO Genitourinary Symposium

Long-term follow-up of Nubeqa for nonmetastatic castration-resistant prostate cancer showed that the drug was safe and effective in treating this patient population.

3 Important Patient-Provider Discussions for Newly Diagnosed Kidney Cancer

3 Important Patient-Provider Discussions for Newly Diagnosed Kidney Cancer

February 27th 2023, 4:01pm

ASCO Genitourinary Symposium

After a patient receives a kidney cancer diagnosis, there are some important conversations to have with their health care team.

What to Expect During Genomic Testing for Prostate Cancer

What to Expect During Genomic Testing for Prostate Cancer

February 22nd 2023, 4:00pm

ASCO Genitourinary Symposium

An expert explains what patients with low-grade prostate cancer can expect when undergoing genomic testing — and why the procedure is important.

Women May Experience Worse Quality of Life Than Men After Bladder Cancer Surgery

Women May Experience Worse Quality of Life Than Men After Bladder Cancer Surgery

February 22nd 2023, 2:00pm

ASCO Genitourinary Symposium

Important data may encourage gender-specific treatment making decisions for patients with bladder cancer.

Ointment Being Studied for Hand-Foot Skin Reaction Related to Kidney Cancer Treatment

Ointment Being Studied for Hand-Foot Skin Reaction Related to Kidney Cancer Treatment

February 21st 2023, 10:00pm

ASCO Genitourinary Symposium

A clinical trial is currently enrolling patients who are experiencing hand-foot skin reaction as a result of kidney cancer treatment.

Survival Is Not Improved by Adding Tecentriq to Chemo for Metastatic Bladder Cancer

Survival Is Not Improved by Adding Tecentriq to Chemo for Metastatic Bladder Cancer

February 20th 2023, 4:00pm

ASCO Genitourinary Symposium

The addition of Tecentriq to platinum-based chemotherapy/gemcitabine did not boost outcomes in patients with metastatic bladder cancer, according to results from the IMvigor 140 trial.

Adding Cabometyx to Immunotherapy Improves Kidney Cancer Outcomes

Adding Cabometyx to Immunotherapy Improves Kidney Cancer Outcomes

February 20th 2023, 2:04pm

ASCO Genitourinary Symposium

The addition of Cabometyx to Opdivo and Yervoy improved outcomes for patients with advanced kidney cancer, according to recent research.

Biomarkers May Predict Outcomes With Padcev to Treat Bladder Cancer Subtype

Biomarkers May Predict Outcomes With Padcev to Treat Bladder Cancer Subtype

February 19th 2023, 7:00pm

ASCO Genitourinary Symposium

Researchers identified several biomarkers that may indicate how a patient responds to Padcev, a type of antibody drug conjugate for patients with urothelial carcinoma, a type of bladder cancer.

Nubeqa, ADT Combo Should Be New Standard of Care for Some Patients With Prostate Cancer

Nubeqa, ADT Combo Should Be New Standard of Care for Some Patients With Prostate Cancer

February 18th 2023, 4:00pm

ASCO Genitourinary Symposium

The combination demonstrated survival benefit in patients with metastatic hormone-sensitive prostate cancer, regardless of risk or volume of disease.

Treatment With Pluvicto Soon After Radium-223 Is Safe, Effective for Prostate Cancer

Treatment With Pluvicto Soon After Radium-223 Is Safe, Effective for Prostate Cancer

February 17th 2023, 2:00pm

ASCO Genitourinary Symposium

The administration of Pluvicto within six months of radium-223 treatment proved to be safe and efficacious in patients with metastatic castration-resistant prostate cancer, research showed.

Nubeqa Outperforms Xtandi, Erleada in Non-metastatic Castration-resistant Prostate Cancer

Nubeqa Outperforms Xtandi, Erleada in Non-metastatic Castration-resistant Prostate Cancer

February 16th 2023, 10:00pm

ASCO Genitourinary Symposium

Patients treated with Nubeqa were less likely to develop disease metastasis or discontinue treatment 6 to 18 months after ARI course start compared to Xtandi or Erleada, according to data presented at ASCO GU.

Adding Avastin to Lonsurf Improved Outcomes in Pretreated Colorectal Cancer

Adding Avastin to Lonsurf Improved Outcomes in Pretreated Colorectal Cancer

January 25th 2023, 2:00pm

ASCO Gastrointestinal Cancers Symposium

Patients with pretreated metastatic colorectal cancer had better outcomes when Avastin was added to their Lonsurf treatment in the third line setting.

SBRT Reduces Side Effects, Treatment Visits in Pancreatic Cancer

SBRT Reduces Side Effects, Treatment Visits in Pancreatic Cancer

January 24th 2023, 10:00pm

ASCO Gastrointestinal Cancers Symposium

Patients with pancreatic cancer who underwent stereotactic body radiation tended to have fewer side effects and treatment sessions compared to those who had intensity-modulated radiation therapy.

Better Quality of Life Reported with Minimally Invasive Esophageal Cancer Treatment

Better Quality of Life Reported with Minimally Invasive Esophageal Cancer Treatment

January 23rd 2023, 10:00pm

ASCO Gastrointestinal Cancers Symposium

Patients who underwent minimally invasive treatment tended to have better quality-of-life outcomes than those who had a full esophagus removal, though there were risk factors for long-term outcomes that should be considered.

Lenvima May Prolong Survival in Advanced Liver Cancer That Progressed on Immunotherapy

Lenvima May Prolong Survival in Advanced Liver Cancer That Progressed on Immunotherapy

January 23rd 2023, 2:00pm

ASCO Gastrointestinal Cancers Symposium

Patients with advanced HCC who progressed after treatment with immunotherapy may have a survival benefit when treated with second-line Lenvima.

Quitting Smoking and Drinking May Decrease Depression Risk After Gastric Cancer Surgery

Quitting Smoking and Drinking May Decrease Depression Risk After Gastric Cancer Surgery

January 22nd 2023, 6:00pm

ASCO Gastrointestinal Cancers Symposium

Patients with gastric cancer who quit smoking and/or drinking after undergoing a gastrectomy tended to have a decreased risk of depression, research showed.

Novel Drug-Chemo Combo May Offer ‘New Standard of Care’ for Certain GI Cancers

Novel Drug-Chemo Combo May Offer ‘New Standard of Care’ for Certain GI Cancers

January 21st 2023, 7:00pm

ASCO Gastrointestinal Cancers Symposium

Zolbetuximab plus mFOLFOX6 lengthened the time to progression for patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma.

HER2-Low Gastric Cancer May Be a Distinct Disease Subtype

HER2-Low Gastric Cancer May Be a Distinct Disease Subtype

January 20th 2023, 10:00pm

ASCO Gastrointestinal Cancers Symposium

Patients with HER2-low gastric cancer tended to have distinct characteristics compared to those with HER2-negative or -positive disease, warranting more research into this group, research found.

Educated Patient® MPN Summit Myelofibrosis Panel: November 19, 2022

Educated Patient® MPN Summit Myelofibrosis Panel: November 19, 2022

December 18th 2022, 3:00pm

Educated Patient® MPN Summit: November 19, 2022

Watch Dr. Aaron Gerds and Dr. Andrew Kuykendall answer questions about myelofibrosis during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Myelofibrosis Second-Line Treatment and Beyond Presentation: November 19, 2022

Educated Patient® MPN Summit Myelofibrosis Second-Line Treatment and Beyond Presentation: November 19, 2022

December 17th 2022, 1:00pm

Educated Patient® MPN Summit: November 19, 2022

Watch Dr. Andrew Kuykendall, from the Mofitt Cancer Center, discuss second-line treatments and beyond for patients with myelofibrosis during the CURE® Educated Patient® MPN Summit.

Educated Patient® MPN Summit First-line Treatment in Myelofibrosis Presentation: November 19, 2022

Educated Patient® MPN Summit First-line Treatment in Myelofibrosis Presentation: November 19, 2022

December 16th 2022, 1:00pm

Educated Patient® MPN Summit: November 19, 2022

Watch to Dr. Naveen Pemmaraju, from The University of Texas MD Anderson Cancer Center, discuss frontline treatment options for patients with myelofibrosis during the CURE® Educated Patient® MPN Summit.

Educated Patient® MPN Summit Polycythemia Vera Panel: November 19, 2022

Educated Patient® MPN Summit Polycythemia Vera Panel: November 19, 2022

December 15th 2022, 1:00pm

Educated Patient® MPN Summit: November 19, 2022

Watch Dr. Jamile Shammo and Dr. John Mascarenhas answer questions about polycythemia vera during the CURE Educated Patient MPN Summit.

Survival and Treatment Response May Be Further Improved With Brukinsa Versus Imbruvica for CLL/SLL

Survival and Treatment Response May Be Further Improved With Brukinsa Versus Imbruvica for CLL/SLL

December 14th 2022, 8:00pm

American Society of Hematology Annual Meeting

Progression-free survival and overall response rates greatly improved in patients with CLL/SLL treated with Brukinsa compared with Imbruvica.

Educated Patient® MPN Summit Future Treatment of Polycythemia Vera Presentation: November 19, 2022

Educated Patient® MPN Summit Future Treatment of Polycythemia Vera Presentation: November 19, 2022

December 14th 2022, 1:00pm

Educated Patient® MPN Summit: November 19, 2022

Watch Dr. John Mascarenhas, from the Icahn School of Medicine at Mount Sinai, discuss future treatments for polycythemia vera, during the CURE Educated Patient MPN Summit.

Calquence Tends to Be a Shorter-Lived Frontline Regimen Than Imbruvica for Leukemia Subtype

Calquence Tends to Be a Shorter-Lived Frontline Regimen Than Imbruvica for Leukemia Subtype

December 13th 2022, 10:00pm

American Society of Hematology Annual Meeting

Patients with chronic lymphocytic leukemia tended to switch to another regimen or intensify their Calquence treatment quicker than those given Imbruvica, study results showed.